FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W35466291> ?p ?o ?g. }

• W35466291 abstract "Abstract Survival, proliferation, and resistance to chemotherapy in CLL cells have been shown to be consistently associated with the activity of the B-cell receptor (BCR) and the associated downstream pathways activated by the BCR. Key molecules in this pathway are LYN and SYK (Spleen tyrosine kinase), as well as PI3K, BTK (Bruton’s tyrosine kinase), and others. Dasatinib, given at standard doses, allows for serum levels well above 11 nM, the IC50 for suppression of LYN kinase. We have previously shown that dasatinib used as a single agent in patients with relapsed CLL results in lymph node responses in 60% of patients and partial responses in 20% of patients as defined by NCI-WG criteria. In the current study, patients with relapsed CLL were treated with a regimen combining dasatinib at 140 mg/day, days 1-14, with fludarabine (F) 25 mg/m2/day, days 1-3, and rituximab (R) 375 mg/m2 per cycle repeated every 28 days, while effective up to 6 cycles. Patients were followed closely for response with CT scans every 2 months initially. Among the first 10 patients treated, all had responses according to IWCLL criteria as follows: The median time to progression was 21 months. In the first week multiple blood samples were taken for analysis of target inhibition and subsequent apoptosis. The schedule of administered agents was altered in the first week to determine which components were associated with which downstream effects. Hence, dasatinib was given on Day 1, no treatment was administered on Day 2, F and R without dasatinib on Day 3, dasatinib with FR on Day 4, and dasatinib with F on Day 5. Initial in vitro studies revealed inhibition of phosphorylation of Lyn at 6 hours after patients were given dasatinib on Days 1 and 4, with recovery by 24 hours. Day 3 treatment with FR but without dasatinib showed no such inhibition at 6 hours. Assessment of global tyrosine phosphorylation in CLL cells showed this same pattern, including that of Syk phosphorylation, specifically. Flow cytometry for annexin-V demonstrated that apoptosis was greatest on Day 4 after 6 hours of exposure to all 3 drugs. We conclude the following: 1) the combination of dasatinib with FR, as seen in the first 10 patients of this study, was associated with excellent responses in blood and lymph nodes as assessed by physical exam, 2) the combination was well tolerated with mainly hematologic toxicity, 3) the inhibition of phosphorylation of Lyn and Syk was associated with apoptosis and clinical response. This combination may have therapeutic promise in advanced CLL and is worthy of further investigation. Disclosures: Off Label Use: Dasatinib use in CLL is off-label. This trial shows that dasatinib may be beneficial in the treatment of CLL. Brown:Pharmacyclics: Consultancy; Genentech: Consultancy; Celgene: Consultancy, Research Funding; Emergent: Consultancy; Onyx: Consultancy; Sanofi Aventis: Consultancy; Vertex: Consultancy; Novartis: Consultancy; Genzyme: Research Funding. Fathi:Seattle Genetics, Inc.: Advisory/Scientific board membership Other, Research Funding; Millennium: Research Funding; Agios: Membership on an entity’s Board of Directors or advisory committees; Teva: Membership on an entity’s Board of Directors or advisory committees." @default.
• W35466291 created "2016-06-24" @default.
• W35466291 creator A5003947352 @default.
• W35466291 creator A5008400421 @default.
• W35466291 creator A5009091754 @default.
• W35466291 creator A5010057352 @default.
• W35466291 creator A5016570475 @default.
• W35466291 creator A5016770040 @default.
• W35466291 creator A5033518868 @default.
• W35466291 creator A5035186913 @default.
• W35466291 creator A5045583767 @default.
• W35466291 creator A5061105669 @default.
• W35466291 creator A5069840184 @default.
• W35466291 creator A5089274301 @default.
• W35466291 creator A5091496002 @default.
• W35466291 date "2013-11-15" @default.
• W35466291 modified "2023-10-01" @default.
• W35466291 title "Inhibition Of Lyn and Syk By Treatment With Dasatinib, Fludarabine, and Rituximab Correlates With Apoptosis and Clinical Response In Patients With Relapsed CLL" @default.
• W35466291 doi "https://doi.org/10.1182/blood.v122.21.5300.5300" @default.
• W35466291 hasPublicationYear "2013" @default.
• W35466291 type Work @default.
• W35466291 sameAs 35466291 @default.
• W35466291 citedByCount "0" @default.
• W35466291 crossrefType "journal-article" @default.
• W35466291 hasAuthorship W35466291A5003947352 @default.
• W35466291 hasAuthorship W35466291A5008400421 @default.
• W35466291 hasAuthorship W35466291A5009091754 @default.
• W35466291 hasAuthorship W35466291A5010057352 @default.
• W35466291 hasAuthorship W35466291A5016570475 @default.
• W35466291 hasAuthorship W35466291A5016770040 @default.
• W35466291 hasAuthorship W35466291A5033518868 @default.
• W35466291 hasAuthorship W35466291A5035186913 @default.
• W35466291 hasAuthorship W35466291A5045583767 @default.
• W35466291 hasAuthorship W35466291A5061105669 @default.
• W35466291 hasAuthorship W35466291A5069840184 @default.
• W35466291 hasAuthorship W35466291A5089274301 @default.
• W35466291 hasAuthorship W35466291A5091496002 @default.
• W35466291 hasConcept C126322002 @default.
• W35466291 hasConcept C143998085 @default.
• W35466291 hasConcept C170493617 @default.
• W35466291 hasConcept C175818844 @default.
• W35466291 hasConcept C203014093 @default.
• W35466291 hasConcept C2776694085 @default.
• W35466291 hasConcept C2776755627 @default.
• W35466291 hasConcept C2779263901 @default.
• W35466291 hasConcept C2779338263 @default.
• W35466291 hasConcept C2779536868 @default.
• W35466291 hasConcept C2780653079 @default.
• W35466291 hasConcept C35174551 @default.
• W35466291 hasConcept C42362537 @default.
• W35466291 hasConcept C502942594 @default.
• W35466291 hasConcept C71924100 @default.
• W35466291 hasConcept C90059517 @default.
• W35466291 hasConcept C98274493 @default.
• W35466291 hasConceptScore W35466291C126322002 @default.
• W35466291 hasConceptScore W35466291C143998085 @default.
• W35466291 hasConceptScore W35466291C170493617 @default.
• W35466291 hasConceptScore W35466291C175818844 @default.
• W35466291 hasConceptScore W35466291C203014093 @default.
• W35466291 hasConceptScore W35466291C2776694085 @default.
• W35466291 hasConceptScore W35466291C2776755627 @default.
• W35466291 hasConceptScore W35466291C2779263901 @default.
• W35466291 hasConceptScore W35466291C2779338263 @default.
• W35466291 hasConceptScore W35466291C2779536868 @default.
• W35466291 hasConceptScore W35466291C2780653079 @default.
• W35466291 hasConceptScore W35466291C35174551 @default.
• W35466291 hasConceptScore W35466291C42362537 @default.
• W35466291 hasConceptScore W35466291C502942594 @default.
• W35466291 hasConceptScore W35466291C71924100 @default.
• W35466291 hasConceptScore W35466291C90059517 @default.
• W35466291 hasConceptScore W35466291C98274493 @default.
• W35466291 hasLocation W354662911 @default.
• W35466291 hasOpenAccess W35466291 @default.
• W35466291 hasPrimaryLocation W354662911 @default.
• W35466291 hasRelatedWork W104449324 @default.
• W35466291 hasRelatedWork W1199719327 @default.
• W35466291 hasRelatedWork W2242208648 @default.
• W35466291 hasRelatedWork W2460851294 @default.
• W35466291 hasRelatedWork W2463427283 @default.
• W35466291 hasRelatedWork W2548530070 @default.
• W35466291 hasRelatedWork W2556728418 @default.
• W35466291 hasRelatedWork W2571403346 @default.
• W35466291 hasRelatedWork W2573030598 @default.
• W35466291 hasRelatedWork W2573814557 @default.
• W35466291 hasRelatedWork W2582681737 @default.
• W35466291 hasRelatedWork W2586476291 @default.
• W35466291 hasRelatedWork W2592602344 @default.
• W35466291 hasRelatedWork W2596636194 @default.
• W35466291 hasRelatedWork W2619773935 @default.
• W35466291 hasRelatedWork W2955571569 @default.
• W35466291 hasRelatedWork W2980172935 @default.
• W35466291 hasRelatedWork W2984230127 @default.
• W35466291 hasRelatedWork W2988237730 @default.
• W35466291 hasRelatedWork W3097293604 @default.
• W35466291 isParatext "false" @default.
• W35466291 isRetracted "false" @default.
• W35466291 magId "35466291" @default.
• W35466291 workType "article" @default.